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Abstract
Background: Epithelial growth factor receptor (EGFR) and KRAS mutation status have been
reported as predictive markers of tumour response to EGFR inhibitors. High resolution melting
(HRM) analysis is an attractive screening method for the detection of both known and unknown
mutations as it is rapid to set up and inexpensive to operate. However, up to now it has not been
fully validated for clinical samples when formalin-fixed paraffin-embedded (FFPE) sections are the
only material available for analysis as is often the case.
Methods: We developed HRM assays, optimised for the analysis of FFPE tissues, to detect somatic
mutations in EGFR exons 18 to 21. We performed HRM analysis for EGFR and KRAS on DNA
isolated from a panel of 200 non-small cell lung cancer (NSCLC) samples derived from FFPE tissues.
Results: All 73 samples that harboured EGFR mutations previously identified by sequencing were
correctly identified by HRM, giving 100% sensitivity with 90% specificity. Twenty five samples were
positive by HRM for KRAS exon 2 mutations. Sequencing of these 25 samples confirmed the
presence of codon 12 or 13 mutations. EGFR and KRAS mutations were mutually exclusive.
Conclusion: This is the first extensive validation of HRM on FFPE samples using the detection of
EGFR exons 18 to 21 mutations and KRAS exon 2 mutations. Our results demonstrate the utility of
HRM analysis for the detection of somatic EGFR and KRAS mutations in clinical samples and for
screening of samples prior to sequencing. We estimate that by using HRM as a screening method,
the number of sequencing reactions needed for EGFR and KRAS mutation detection can be reduced
by up to 80% and thus result in substantial time and cost savings.
Background
Lung cancer is the leading cause of cancer-related death,
accounting for one third of all cancer mortality worldwide
due to high incidence, advanced stage at diagnosis and
aggressive tumour behaviour [1]. Non-small cell lung can-
cer (NSCLC), comprising 80% of all lung cancer cases, has
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a poor prognosis if diagnosed at an advanced stage. There
is a low median survival of less than one year after diagno-
sis when treated by conventional chemotherapy [2].
The epidermal growth factor receptor (EGFR) is a member
of the ErbB receptor tyrosine kinase family. EGFR has
been found to be over-expressed in a variety of human
malignancies [3,4]. Activation of EGFR results in the initi-
ation of a diverse range of cellular signalling pathways,
including cell proliferation and protection of the cell from
apoptosis [5,6]. Activating mutations in the tyrosine
kinase domain of the EGFR gene (EGFR) have been
shown to be associated with a dramatic response to the
tyrosine kinase inhibitors (TKIs), such as gefitinib and
erlotinib [7-10]. These mutations are located in exons 18
to 21 and are more common in females, non-smokers,
tumours with a histological diagnosis of adenocarcinoma,
and individuals of Asian descent [11]. In cell line studies,
these mutations have been shown to induce oncogenic
transformation of fibroblasts and lung epithelial cells
[7,12-15].
KRAS is a member of the Ras gene family which encode
small G proteins with intrinsic GTPase activity. The KRAS
protein plays a key role in Ras/MAPK signalling which is
involved in multiple pathways including proliferation,
differentiation and apoptosis [16]. KRAS  mutations
which are found in 33% of NSCLC are restricted to spe-
cific codons; more commonly codons 12 and 13 in exon
2 and rarely codons 59 and 61 in exon 3 [16,17]. These
mutations alter the conformation of KRAS causing
impaired GTPase activity resulting in the protein being
constitutively active. KRAS mutation testing is an impor-
tant adjunct to EGFR testing because KRAS mutations are
significantly associated with absence of responsiveness to
EGFR  inhibitors and are mutually exclusive to EGFR
mutations [18-20]. Thus, the mutational status of EGFR
and KRAS can provide important information for stratifi-
cation of NSCLC patients to receive molecularly targeted
treatment with tyrosine kinase inhibitors.
Currently, the most widely used method for EGFR and
KRAS mutation detection is direct sequencing. To be suc-
cessful, the sequencing methodology requires a sufficient
amount of tumour material of relatively good quality,
which is difficult to obtain from cancer patients with
inoperable tumours. In addition, the high cost, limited
sensitivity and time consuming nature of sequencing has
prompted the development of alternative methods that
are more cost effective, faster, easier to perform, and more
sensitive. The relatively low sensitivity of sequencing in
somatic mutation detection [21] is a particular problem in
lung cancer where biopsies are often small and often con-
tain only a small proportion of neoplastic cells. Studies
using denaturing high performance liquid chromatogra-
phy (DHPLC) have found additional EGFR mutations,
which were undetected by sequencing [22-24]. However
DHPLC, requiring extra sample handling after PCR ampli-
fication and expensive instrumentation, is relatively slow
as the samples can only be analysed sequentially.
High resolution melting (HRM) analysis is a recently
developed methodology that has enormous potential for
the detection of DNA sequence changes [25]. New instru-
ments combined with DNA intercalating dyes that can be
used at saturating concentrations allow the discrimina-
tion of sequence changes in PCR amplicons without man-
ual handling of PCR products. The recent application of
HRM to mutation scanning and SNP genotyping as well as
DNA methylation studies have been demonstrated [26-
31]. In particular, the HRM methodology has shown great
promise for the detection of heterozygous germline muta-
tions as well as somatic mutations e.g. in the KIT, BRAF
and TP53 genes [26,32,33].
Formalin fixation followed by paraffin embedding of tis-
sue specimens is a widely used preservation method
because it helps to maintain morphological features of the
tissue specimen [34]. However, irreversible damage to
DNA can occur during this process or subsequent pro-
longed storage, resulting in an adverse effect on DNA
quality [35].
As FFPE tissues are the most common clinical specimens
used for detection of the EGFR and KRAS mutations, the
validation of HRM using DNA samples extracted from
FFPE tissues is essential for its application as a screening
method for mutation detection in these genes. In this
study, we developed HRM assays to evaluate the efficacy
of this methodology for screening EGFR  mutations in
exons 18 to 21 using a panel of 200 NSCLC FFPE biopsies.
KRAS exon 2 mutations at codon 12 and 13 were also
screened in this sample set using a previously described
HRM assay.
Methods
Samples
A total of 200 lung cancer biopsy specimens were analysed
from specimens sent to the Peter MacCallum Cancer Cen-
tre, Melbourne, Australia for EGFR mutation detection by
direct sequencing. These patients were often referred for
EGFR mutation testing by clinicians since their clinical
features and history were suggestive of those previously
reported for patients with EGFR-associated mutations;
histological diagnosis of adenocarcinoma, female gender,
non-smoker status and Asian ethnicity. Of the 200 sam-
ples, 141 were adenocarcinomas, 24 were large cell carci-
nomas, 10 were squamous cell carcinomas, and 25 were
of other or unknown histologies. The samples were inde-
pendently assessed by pathologists from both the refer-BMC Cancer 2008, 8:142 http://www.biomedcentral.com/1471-2407/8/142
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ring hospital, and from the Peter MacCallum Cancer
Centre. Tumour-rich areas on a hematoxylin and eosin
slide were marked by the pathologist to ensure that the
maximum amount of tumour material was collected for
the genetic testing. Written informed consent was
obtained from all patients or families prior to testing. This
study was approved by the Ethics of Human Research
Committee at the Peter MacCallum Cancer Centre
(project number 03/90).
DNA extraction from formalin-fixed paraffin-embedded 
(FFPE) tissue
Tissue sections of 5 μm thickness were obtained from
FFPE tissues and stained with Methyl green. The tumour-
rich areas were micro-dissected using a 21G needle and
the samples underwent proteinase K digestion in a rotat-
ing incubator at 56°C for 3 days. Genomic DNA was
extracted using the DNeasy Tissue kit (Qiagen, Hilden,
Germany) according to the manufacturer's protocol and
was kept at 4°C before use.
Design of HRM primers
Several factors were taken into account during the design
of primers for this study. As FFPE DNA was used, primers
that would yield reproducible amplification from
degraded templates, or DNA in which the quality has been
compromised were designed. As a result, primers giving
rise to shorter amplicons were chosen as they are more
likely to result in satisfactory amplification from degraded
FFPE DNA. Furthermore, existing primer pairs that were
used for the sequencing of EGFR exons 18 to 21 (Table 1)
were found to be inappropriate for HRM as, with these
longer amplicons (233, 294, 356 and 295 bp for exons 18
to 21 respectively), samples harbouring mutations were
not efficiently distinguished from wild type samples in
melting analysis. We thus chose to design primers that
flanked the exons as closely as possible. As single nucle-
otide polymorphisms (SNPs) cannot be readily distin-
guished from mutations by HRM analysis, designing
shorter amplicons in this way also minimises the inclu-
sion of these confounding sequence variants. Most
intronic SNPs can thus be excluded from the amplicons. If
a SNP is close to the exon boundary, the primer can be
placed over the SNP and a mismatched base with no
allelic preference can be introduced at the SNP position
[26]. Thus, the base 'A' was incorporated at the
c.2184+19G>A position within the EGFR exon 18 reverse
primer. The primers were designed to have annealing tem-
peratures of around 60°C as predicted by Primer Express
1.5 software (Applied Biosystems, Foster City, CA). Each
amplicon was analysed to ensure that it contained only a
single melting domain using the Poland algorithm [36].
HRM assays
The EGFR HRM primer sequences are shown in Table 1.
EGFR exon 18, 19 and 21 HRM primers were designed to
span the entire exon with product sizes of 199, 250 and
210 bp respectively. EGFR exon 20 was amplified in two
fragments (ex20a and ex20b) with product sizes of 121 bp
Table 1: EGFR HRM and sequencing primer sequences
Exon Primer name Sequence Amplicon size
Sequencing#
18 EGFR18_m13_F 5'-CATGGTGAGGGCTGAGGTGA-3' 233 bp
EGFR18_m13_R 5'-CCCCACCAGACCATGAGAGG-3'
19 EGFR19_m13_F 5'-GTGCATCGCTGGTAACATCCA-3' 294 bp
EGFR19_m13_R 5'-GGAGATGAGCAGGGTCTAGAGCA-3'
20 EGFR20_m13_F 5'-CGCATTCATGCGTCTTCACC-3' 356 bp
EGFR20_m13_R 5'-CTATCCCAGGAGCGCAGACC-3'
21 EGFR21_m13_F 5'-TGGCATGAACATGACCCTGAA-3' 295 bp
EGFR21_m13_R 5'-CAGCCTGGTCCCTGGTGTC-3'
HRM
18 EGFR_ex18_F 5'-CATGGTGAGGGCTGAGGTGA-3' 199 bp
EGFR_ex18_R 5'-CCAGAGG(A*)CTGTGCCAGGGAC-3'
19 EGFR_ex19_F 5'-GTGCATCGCTGGTAACATCCA-3' 250 bp
EGFR_ex19_R 5'-AAAGGTGGGCCTGAGGTTCA-3'
20a EGFR_ex20a_F 5'-AAGCCACACTGACGTGCCTCT-3' 121 bp
EGFR_ex20a_R 5'-GCGTGATGAG(G*)TGCACGGT-3'
20b EGFR_ex20b_F 5'-CCTCCACCGTGCA(C*)CTCATC-3' 146 bp
EGFR_ex20b_R 5'-CCCGTATCTCCCTTCCCTGA-3'
21 EGFR_ex21_F 5'-CCTCACAGCAGGGTCTTCTCTG-3' 210 bp
EGFR_ex21_R 5'-TGGCTGACCTAAAGCCACCTC-3'
# M13 sequences (not shown) are attached to all sequencing primers.
(*) indicates the position of the mismatched base which is introduced to prevent SNP interference and allele-specific PCR for the common SNPs 
c.2184+19G>A and c.2361G>T, in intron 18 and exon 20 respectively.BMC Cancer 2008, 8:142 http://www.biomedcentral.com/1471-2407/8/142
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and 146 bp. The KRAS exon 2 primers which amplified a
92 bp product were described previously [37].
PCR for HRM analysis was performed in 0.1 ml tubes on
the Rotor-Gene 6000™ (Corbett Research, Sydney, Aus-
tralia) in the presence of the fluorescent DNA intercalat-
ing dye, SYTO 9 (Invitrogen, Carlsbad, CA). The reaction
mixture in a 20 μl final volume contained; 1× PCR buffer,
2.5 mM MgCl2, 200–400 nM forward primer, 200–400
nM reverse primer, 5 ng of genomic DNA, 200 μM of
dNTPs, 5 μM of SYTO 9, 0.5 U of HotStarTaq (Qiagen)
polymerase and PCR grade water. The cycling and melting
conditions for EGFR exons 18 to 21 were as follows; one
cycle of 95°C for 15 min; 45–50 cycles of 95°C for 10 s,
65°C for 10 s with an initial 10 cycles of touchdown
(1°C/cycle), 72°C for 30 s; one cycle of 97°C for 1 min
and a melt from 70°C to 95°C rising 0.2°C per second.
The cycling and melting conditions for KRAS exon 2 were
as follows; one cycle of 95°C for 15 min; 50 cycles of
95°C for 10 s, 67.5°C for 5 s with an initial 10 cycles of
touchdown (1°C/cycle), 72°C for 20 s; one cycle of 97°C
for one min and a melt from 70°C to 95°C rising 0.2°C
per second. The genomic DNA was diluted to 2.5 ng/μl (5
ng tested) to provide a consistent testing condition. All
samples were tested in duplicate.
HRM analysis
High resolution melting analysis was performed on the
Rotor-Gene 6000 Software (v1.7) and analysed by two sci-
entists who were blinded to the sequencing results. The
normalised graph and the difference graph were used to
analyse the data. The normalised graph was generated by
the monitoring of dissociation of the fluorescent dye from
double-stranded DNA as the temperature increased. The
dye (SYTO 9) used in the current study can only fluoresce
when it is intercalated into double-strand DNA. The nor-
malised graph shows the degree of reduction in fluores-
cence over a temperature range (typically 70°C to 95°C).
All samples including the wild-type were plotted accord-
ing to their melting profiles. In the difference graph, the
melting profiles of each sample were compared to that of
the wild-type which was converted to a horizontal line.
Significant deviations from the horizontal line (relative to
the spread of the wild type controls) were indicative of
sequence changes within the amplicon analysed. Samples
with aberrant melting curves were recorded as HRM muta-
tion positive. HRM results were compared with sequenc-
ing results for the validation of HRM analysis in the
detection of EGFR mutations.
DNA sequencing
All samples were sequenced for the detection of EGFR
mutations in exons 18 to 21 using M13 tagged primers
(Table 1). The reaction mixture in a total of 25 μl con-
tained the following; 1× PCR buffer, 2.5 mM MgCl2, 200
nM of each primer, 50 ng of genomic DNA (if possible),
200 μM of dNTPs, 0.5 U of HotStarTaq polymerase and
PCR grade water. The PCR reaction was performed using
the following conditions; initial denaturation at 95°C for
15 min; 40 cycles of 94°C for 45 s, 65°C for 45 s, 72°C
for 45 s; one cycle of 72°C for 10 min. 6 μl of the PCR
products were purified with ExoSapIT (GE Healthcare, Lit-
tle Chalfont, England) followed by a sequencing reaction
with Big Dye Terminator v3.1 (Applied Biosystems, Foster
City, CA) according to the manufacturer's protocol. The
sequencing products were ethanol precipitated before
running on a 3100 Genetic Analyser (Applied Biosys-
tems). The sequencing data was visualized using
Sequencher 4.6 (Gene Codes Corporation, Ann Arbor,
MI) and was independently analysed by two scientists.
Each mutation was confirmed by sequencing a second
independent PCR reaction.
Samples were sequenced for KRAS exon 2 mutations using
an 189 bp amplicon. The sequencing primers were
described previously [37]. The reaction mixture in a total
of 20 μl was made using HotStarTaq (Qiagen) and con-
tained the following; 1× PCR buffer, 2.5 mM MgCl2, 200
nM of each primer, 5 ng of genomic DNA, 200 μM of
dNTPs, 0.5 U of Taq polymerase and PCR grade water PCR
reactions were performed using the following conditions;
initial denaturation at 95°C for 15 min; 50 cycles of 95°C
for 10 s, 67.5°C for 10 s, 72°C for 20 s with an initial 10
cycles of touchdown (1°C/cycle); one cycle of 72°C for 10
min. Sequencing reactions were performed as above
except that an annealing temperature of 60.7°C and an
extension temperature of 72°C were used.
Results
EGFR mutation detection by direct sequencing
EGFR exons 18 to 21 were sequenced using genomic DNA
extracted from FFPE tissues from the 200 NSCLC patients.
In total, 73 samples were identified with EGFR mutations
by sequencing (Table 2). The EGFR mutations were most
common in exon 19, comprising 61% (46/75) of all
mutations found, followed by exon 21 missense muta-
tions in 18% (14/75). Ten mutations in exon 20 (13%)
and five mutations in exon 18 (6%) were also detected.
There were three cases of rare mutations. A 4 bp deletion
and 1 bp insertion (p.E709_T710delinsD) and a 9 bp
deletion (p.A767_V769del) mutations were detected in
exons 18 and 20 respectively. In exon 19, there was a
novel in-frame 18 bp insertion mutation that replaced the
glutamic acid at p.746 by valine and inserted six amino
acids (PVAIKE) afterwards (Table 2).
We also found two samples harbouring double mutations
in exons 18 and 20. The mutation in exon 20 in both indi-
viduals was the same missense substitution (p.S768I). TheBMC Cancer 2008, 8:142 http://www.biomedcentral.com/1471-2407/8/142
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exon 18 mutations were p.G719S and p.G724S. The com-
bination of p.G719S and p.S768I mutations has been
reported previously in NSCLC samples [38].
Two novel synonymous mutations, p.A763A (c.2289C>T)
and p.N771N (c.2313C>T), were found in exon 20. A
novel intronic variant with C>T at c.2469+21 was found
in a single patient. These may represent passenger muta-
tions or rare SNPs although the germline DNA was not
able to be tested to distinguish the two possibilities
HRM assay with different amounts of DNA template
In many NSCLC cases, the FFPE specimens available for
analysis are often small in size. To investigate whether
HRM assay can be performed on a small amount of DNA
template, DNA amounts ranging from 1 to 100 ng (1, 5,
10, 25, 50 and 100 ng) were tested using a sample with an
exon 19 p.E746_A750 deletion mutation present at 50%
mutant allele frequency.
Distinctive heteroduplex melting patterns were detected
across the entire range of DNA template amounts, featur-
ing an earlier melting of amplicon at the initial melting
stage and becoming more stable at later stages compared
with the wild-type (Figure 1. Panel A). In particular, the
melting curve from 1 ng of mutant template was suffi-
ciently different from wild-type to identify the mutation,
and this distinct melting profile was consistently seen
across all the other template amounts investigated. This
illustrates the sensitivity of the technique as mutations
can be detected in samples with as little as 1 ng of tem-
plate DNA by HRM analysis.
After confirming that HRM can be performed with a small
amount of template DNA, we further tested the practical-
ity of HRM using a panel of samples with different DNA
concentrations, ranging from 8 ng to 651 ng. All samples
harboured the same EGFR exon 19 p.E746_A750 deletion
mutation. Again, all mutant samples exhibited distinct
melting characteristics from wild-type, and could easily be
identified as mutants (Figure 1. Panel B).
These analyses demonstrated that reliable results could
also be obtained when more than 1 ng of template DNA
Table 2: Summary of EGFR mutations detected by sequencing from the 200 NSCLC samples
Exon Mutation type Nucleotide Change AA change N
18 missense c.2126A>C p.E709A 1
c.2155G>A * p.G719S 1
c.2156G>C p.G719A 1
c.2170G>A * p.G724S 1
deletion/insertion c.2127_2130del4insC p.E709_T710delinsD 1
19 deletion/insertion c.2233_2245del15 p.K745_D749del 1
c.2235_2249del15 p.E746_A750del 19
c.2235_2249del15insTTC p.E746_A750delinsF 1
c.2236_2250del15 p.E746_A750del 9
c.2237_2251del15 p.E746_A750del 1
c.2237_2252del16insT p.E746_A750delinsV 2
c.2237_2238ins18 p.E746VinsPVAIKE 1
c.2239_2248del10insC p.L747_D749delinsP 1
c.2239_2251del13insC p.L747_T751delinsP 1
c.2239_2258del20insCA p.L747_P753delinsQ 1
c.2240_2254del15 p.L747_T751del 2
c.2240_2257del18 p.L747_P753delinsS 6
c.2252_2276del25insA p.T751_I759delinsN 1
20 missense c.2303G>T p.S768I 3
deletion/insertion c.2300_2308del9 p.A767_V769del 1
c.2309_2310insCCAGCGTGG p.D770_H773insGSVD 1
c.2311A>G, 2312_2313insGGT p.N771_P772insGY 1
c.2317delCinsTACAACCCCT p.H773_R776insYNPY 1
c.2322_2323insCCACGT p.C775_R776insPA 1
silent mutation c.2289C>T p.A763A 1
c.2313C>T p.N771N 1
21 missense c.2506C>T p.R836C 1
c.2573T>G p.L858R 13
Total 75
75 mutations were seen in 73 patients. AA: amino acid, N: number of samples.
* These samples showed an additional exon 20 c.2303G>T (p.S768I) mutation.BMC Cancer 2008, 8:142 http://www.biomedcentral.com/1471-2407/8/142
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was tested by HRM. For the samples that amplified well,
the variation in the amount of template within samples
had minimal influence on the HRM analysis, indicating
that adjusting the amount of template might normally be
unnecessary.
EGFR and KRAS mutation detection by HRM analysis
All 200 NSCLC samples were tested by HRM for the detec-
tion of mutations in EGFR exons 18 to 21 and KRAS exon
2. The EGFR HRM assays gave 23, 67, 23 and 41 results
that were scored as HRM positive in exons 18 to 21 respec-
tively (Table 3). All mutations identified by sequencing
were correctly identified by HRM assays giving a sensitiv-
ity of 100%. The difference plots for EGFR exons 18 to 21
and sequencing traces of positive samples are shown in
Figures 2 and 3.
However, HRM indicated more positive samples than
sequencing for all of the EGFR exons. A total of 45 sam-
ples were positive only by HRM. There were 18, 21, 13 and
18 apparently false positive results from exons 18 to 21
respectively. Significantly, seven samples were positive in
three or four EGFR HRM assays, and eight samples were
positive in two assays. Most of these are likely to be true
false positives due to degraded DNA from the FFPE speci-
men. Thirty samples were positive in a single assay only.
Compared to other assays, the number of samples with
discrepant results was lower in the exon 20 assays where
relatively shorter amplicons were tested, further highlight-
ing the importance of using shorter HRM amplicons to
enhance the reliability of the results.
KRAS exon 2 mutations at codons 12 to 13 were screened
by our previously described HRM assay [28] that gener-
ated a 92 bp PCR amplicon (Figure 4). Twenty-five sam-
ples of the 200 tested (12.5%) were scored as HRM
positive. These samples were negative for EGFR mutations
by both sequencing and HRM.
All 25 KRAS exon 2 HRM positive samples proved to have
a mutation at codons 12 or 13 when tested by sequencing
(Table 4). Seven different KRAS mutations were observed
Difference plots showing mutation detection with various amounts of starting template Figure 1
Difference plots showing mutation detection with various amounts of starting template. In difference plots, the 
melting profile of a wild type control is chosen as a horizontal base line and the relative differences in the melting of all the 
other samples are plotted relative to this baseline. Panel A: A difference plot of EGFR exon 19 using different amounts of tem-
plate from one sample. Different amounts of template, ranging from 1 ng to 100 ng, were assessed by the EGFR exon 19 assay 
using a sample with a p.E746_A750 deletion mutation. A near identical heteroduplex type melting pattern is observed from 
each amount of template tested. The wild-type control sample is shown as a horizontal line (in blue). Panel B: A difference 
plot of EGFR exon 19 using different samples with different amounts of template. Each sample contained the same p.E746_A750 
in-frame deletion mutation but the samples were at different DNA concentrations and from different individuals. A wild-type 
control sample is shown as a horizontal line (in blue). All samples show different melting patterns compared to the wild-type.BMC Cancer 2008, 8:142 http://www.biomedcentral.com/1471-2407/8/142
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amongst the 25 mutation positive samples, comprising 5
mutations at codon 12 (8 p.G12C, 7 p.G12D, 5 p.G12V,
1 p.G12F and 1 p.G12A) and 2 mutations at codon 13 (2
p.G13C and 1 p.G13V). In addition, 25 samples that were
both EGFR mutation negative and KRAS mutation nega-
tive were sequenced for KRAS exon 2. All showed normal
KRAS sequence.
Discussion
The advent of molecularly targeted therapy is shifting the
paradigm of management of cancer patients from general-
ised chemotherapy and/or radiotherapy to personalised
treatments with better efficacy and lower toxicity. An
example of this is the development of EGFR  tyrosine
kinase inhibitors in the management of NSCLC patients
Difference plots and sequence traces for EGFR exons 18 and 19 Figure 2
Difference plots and sequence traces for EGFR exons 18 and 19. Panel A: The difference plot of EGFR exon 18 shows melting profiles for three 
positive samples (TX36 in purple, TX53 in orange and TX290 in red). Panel B: Sequencing chromatograms show a p.E709A in TX36, a p.G719S in TX53 
and a p.E709_T710delinsD in TX290. Panel C: The difference plot of EGFR exon 19 shows melting profiles for three positive samples (TX127 in brown, 
TX142 in red and TX186 in orange). Panel D: Sequencing chromatograms show a p.L747_P753delinsS in TX127, a p.E746_A750del in TX142 and a 
p.E746_A750delinsF mutation in TX186.BMC Cancer 2008, 8:142 http://www.biomedcentral.com/1471-2407/8/142
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where the presence of predictive markers such as EGFR
and KRAS mutations in their tumours stratifies patients to
receive the appropriate treatment.
Currently, direct sequencing is the standard method for
EGFR mutation detection, but its limited sensitivity, high
cost and long turnaround time have prompted the devel-
opment of alternative methods for routine clinical testing
which have greater diagnostic practicality for somatic
mutation detection.
HRM has recently been introduced as a screening method
for mutation detection. It is an in-tube method which can
be performed in a fast, cheap, and robust manner. It has
Difference plots and sequence traces for EGFR exons 20 and 21 Figure 3
Difference plots and sequence traces for EGFR exons 20 and 21. Panel A: The difference plot of EGFR HRM exon 20a shows different melting pro-
files of three positive samples (TX53 in red, TX383 in brown and TX440 in orange). Panel B: A p.S768I in TX53, a p.H773_R776insYNPY in TX383 and a 
p.D770_H773insGSVD in TX440 mutation are detected by sequencing from the HRM positive samples. Panel C: The difference plot of EGFR HRM exon 
21 shows three HRM positive samples (TX23 in red, TX44 in purple and TX324 in orange). Panel D: Sequencing chromatograms show a p.R836R SNP in 
TX23, a p.R836C in TX44 and a p.L858R mutation in TX324.BMC Cancer 2008, 8:142 http://www.biomedcentral.com/1471-2407/8/142
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been applied to the detection of both germline and
somatic mutations. For heterozygous germline mutations,
HRM has sensitivities approaching 100% [32,39]. For
somatic mutations in tumours, detection can be compro-
mised by a low proportion of tumour cells in the biopsy.
In practice, it has been shown previously that mutant alle-
les at levels as low as 5 to 10% can be detected by HRM for
KRAS exon 2 mutations [29,37].
HRM has previously been used for detection of EGFR
mutations. In lung cancer, the two most common types of
EGFR mutation, exon 19 deletions and exon 21 p.L858R,
were screened by HRM, with a reported 92% sensitivity
compared with direct sequencing [29,40]. In head and
neck cancer, EGFR exons 18 to 21 were screened by HRM,
resulting in the detection of two EGFR mutations in 24
squamous cell carcinomas [28].
We designed this study to determine whether HRM can be
a diagnostically useful screening method for EGFR and
KRAS mutations in clinical FFPE specimens by validating
HRM against sequencing in a large sample cohort contain-
ing various types of EGFR and KRAS mutations.
Each of the previously described HRM mutation screening
assays for EGFR have limitations preventing them from
Difference plots and sequence traces for KRAS exon 2 mutations Figure 4
Difference plots and sequence traces for KRAS exon 2 mutations. In the difference plot for KRAS exon 2, the melting 
curves from the four samples (TX23 in purple, TX41 in green, TX55 in orange and TX64 in brown) and a positive mutation 
control (RPMI8226 in red) were compared to a wild-type sample. The wild-type control sample is shown as a horizontal line in 
blue. Four patients and the positive control samples had different melting profiles compared to the wild-type. Sequencing of the 
patients revealed four different amino acid changes at codon 12; p.G12D in TX23, p.G12F in TX41, p.G12V in TX55 and 
p.G12C in TX64.
Table 3: Summary of EGFR mutation testing by sequencing and HRM
Exon SEQ Positive HRM Positive HRM positive only Sensitivity (%) Specificity (%)
18 5 23 18 100 91
19 46 67 21 100 88
20 10 23 13 100 93
21 23* 41 18 100 91
* The nine samples containing the SNP c.2508C>T were included.
SEQ: sequencing, HRM: high resolution melting.BMC Cancer 2008, 8:142 http://www.biomedcentral.com/1471-2407/8/142
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being practical for one or more of the following reasons:
they do not cover all of exons 18 to 21 [29,40], they do
not discriminate against common SNPs leading to unnec-
essary sequencing [28], they do not detect all mutations
that are detectable by sequencing [29,40] and they have
not been validated against a large panel of clinical sam-
ples with previously determined mutations [28].
In one assay, a primer is located over the c.2184+19 com-
mon SNP potentially resulting in non-amplification of
the mutant allele [28]. Allele dropout due to sequence var-
iation at the primer binding site has been previously dem-
onstrated [41]. If the allele that has not amplified contains
the mutation, the mutation will not be detected.
In this study, HRM assays were designed to maximise the
benefits of HRM screening and to minimise SNP interfer-
ence. EGFR exon 18 to 21 assays covering the entire cod-
ing regions were developed. The incorporation of
mismatched bases at SNP loci within the primer
sequences made it possible to exclude two SNPs,
c.2361G>A and c.2184+19G>A. Under the conditions
used in our assays, this did not preclude efficient amplifi-
cation of both alleles, allowing us to detect all 15 muta-
tions from exons 18 and 20.
Due to its high frequency, the exonic SNP, c.2361G>A,
would normally necessitate nearly 50% of samples being
sequenced for exon 20 because the heterozygous melting
pattern given by the SNP can not readily be distinguished
from mutation by HRM. Fortunately, its position, in the
middle of a large exon, allowed us to divide exon 20 into
two fragments using two overlapping amplicons with PCR
product sizes of 121 bp and 146 bp. Primers which over-
laid the SNP and contained a mismatched residue at the
SNP location were used for both amplicons to exclude the
SNP from being detected by HRM. A 'G' and an 'A' respec-
tively (mismatched to both alleles) were introduced at
c.2361 into the exon 20a reverse and exon 20b forward
primers. This strategy led to a short region of 15 bp
(c.2353_2367) flanking the SNP for which mutations
could not be detected. This is not a serious limitation as
no mutations have so far been reported in that region
[42].
The other common exonic SNP, c.2508C>T in exon 21, is
present at a much lower frequency and thus necessitated
only a comparatively small increase in the amount of
sequencing that would be required. The SNP was detected
in nine of the 200 samples.
It is important to consider the amplification information
when interpreting HRM results. Instruments allowing the
real time monitoring of amplification are advantageous in
this regard. We observed that melting curves from samples
with insufficient amplification tended to be shifted to the
right relative to the wild-type curves in the normalised
plots. This implies that the amount of the amplifiable
(functional) templates varies in each sample depending
on the degree of DNA degradation even though they are
all adjusted to the same concentration (2.5 ng/μl). For
those samples, we diluted the wild-type control DNA to
get similar amplification to the samples with insufficient
amplification. We also increased the amplification cycle
number to 60 to allow sufficient amplification for melting
analysis. As shown in Figure 5, with sufficient amplifica-
tion, the right shifting of melting curves was corrected and
thus the patient DNA could be reliably compared to the
wild-type.
Accurate identification of mutations is a crucial aspect of
all mutation screening methods. This current study dem-
onstrates the accuracy of HRM in the detection of EGFR
and KRAS mutations in a panel of 200 NSCLC samples.
Seventy-five  EGFR  mutations and 25 KRAS  mutations
were identified by HRM analysis in concordance with
sequencing results. The mutation types for each exon were
similar to those reported in previous studies, in-frame
deletions in exon 19, insertions in exon 20 and missense
mutations in both exon 18 and 21 [7-9]. However, the
overall mutation rate (37.5%) in this Australian study was
much higher than in North America and Western Europe
(10%) but similar to East Asian populations (30–50%)
[43-47]. Although most Australians are of European
descent, the higher EGFR mutation rate is likely to be due
to selection bias of patients by referring oncologists for
features associated with EGFR mutation. The pre-selection
criteria included tumours that were histologically adeno-
carcinomas (70% of samples tested) and patients that
were female (60% of patients tested) and/or of Asian eth-
nicity as many of the patients had a name that was consist-
ent with Asian ancestry. The KRAS mutation rate (12.5%)
which is lower than that reported in previous studies
[16,17] also supports the notion of pre-selection bias.
Table 4: Summary of KRAS exon 2 mutations detected by HRM 
and sequencing
Mutation AA change N
c.34G>T p.G12C 8
c.34_35GG>TT p.G12F 1
c.35G>A p.G12D 7
c.35G>T p.G12V 5
c.35G>C p.G12A 1
c.37G>T p.G13C 2
c.38_39C>TT p.G13V 1
Total 25
AA: amino acid, N: number of samplesBMC Cancer 2008, 8:142 http://www.biomedcentral.com/1471-2407/8/142
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Although all positive sequencing results were detected by
HRM, some samples were considered positive by HRM
but were negative by sequencing (Table 3). There are sev-
eral possible explanations. One possible explanation is
that the adverse effects of formalin fixation on DNA can
cause PCR artefacts during amplification. At least four
chemical reactions occur between formaldehyde and
DNA; methylol formation, methylene bridge formation,
apurinic and apyrimidinic site formation, and hydrolysis
of the phosphodiester bonds [48]. Compared to the DNA
extracted from frozen tissues, a higher frequency of non-
reproducible sequence alterations have been reported
with DNA isolated from the formalin fixed tissues [49,50].
Therefore, the cumulative effects of the PCR artefacts
either from Taq polymerase error and errors attributed
from chemical reactions of formalin on DNA influence
the melting profile of the amplicon depending on the
degree of DNA damages.
Influence of amplification status on melting analysis Figure 5
Influence of amplification status on melting analysis. Panel A: The amplification plot of EGFR exon 19 shows insufficient amplification of several 
samples relative to the wild-type (blue). Panel B: The subsequent melting analysis of the same samples on a normalised plot shows the right shift of curves 
from the wild-type. Panel C: Dilution (1 in 20) of the wild-type (aqua) and the addition of 15 cycles allowed all samples to achieve similar levels of amplifi-
cation. Panel D: The normalised plot now shows no aberrant right shifting of melting curves, identifying TX441 as mutation positive and TX454 and 
07M708 as mutation negative.BMC Cancer 2008, 8:142 http://www.biomedcentral.com/1471-2407/8/142
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Seven samples gave positive results in more than three
EGFR  HRM assays, supporting the hypothesis that the
quality of DNA is one of the factors causing aberrant vari-
ation of melting in HRM analysis. It has been observed
that the wild-type variation in melting analysis is much
greater with FFPE DNA than DNA from frozen tissues or
peripheral blood (data not shown). The amount of false
positives decreased with decreasing amplicon length, with
EGFR exon 19 (amplicon size 250 bp) giving the most
false positives and KRAS exon 2 (92 bp) giving the least.
Another possibility is that some samples contained levels
of mutation below the sensitivity of sequencing detection
as a result of a low percentage of tumour in the sample or
genetic heterogeneity within the tumour. Where sequenc-
ing requires the mutation to be present at a level of 20%
of the sample, HRM can detect heterozygous genetic
changes down to 10% or below [26,29,37]. We are now
adopting digital techniques to confirm that some speci-
mens have true mutations present at low levels. Other
HRM false positives can arise from PCR errors due to
amplification from very low levels of template. True muta-
tions can be distinguished from artefacts by confirming
the identical sequence variations from independent
amplification (Do and Dobrovic, manuscript submitted).
HRM is a suitable methodology to test FFPE samples as
well as samples with a very low quantity of DNA. It has
been reported that ten percent buffered formalin, an aque-
ous dilution of formaldehyde, can interact with DNA and
initiate irreversible DNA degradation resulting in an
adverse effect on DNA quality [35]. In our HRM assays, all
the samples were successfully amplified and analysed.
Our results show that HRM can be performed with as little
as 1 ng template in the EGFR exon 19 HRM assay. This
level of sensitivity of HRM, together with the possibility of
sequencing of the HRM product, will extend our ability to
screen even clinical samples with extremely low DNA
quantity such as samples taken from patients with inoper-
able tumours. HRM analysis can now provide a genetic
testing option for these patients, in which the results
might prove useful in directing treatment and may ulti-
mately improve outcomes.
EGFR and KRAS mutations are predominantly mutually
exclusive with very rare tumours containing both genes
mutated [44,51]. The coexistence of mutations in both
EGFR and KRAS has only been reported in two patients
[52]. In the current study, all 25 KRAS positive samples
were wild-type for EGFR, supporting the general mutual
exclusiveness of the two mutations.
Conclusion
We have established a fast, efficient and reproducible
screening method for EGFR and KRAS mutation detection
by which degraded DNA from FFPE tissues can be tested.
This is the first study in which the HRM method has been
properly validated as a scanning method for EGFR and
KRAS mutations in a large sample set showing accurate
mutation detection with 100% sensitivity. It is estimated
that up to 80% of sequencing reactions can be eliminated
for these two genes if samples are screened by HRM. These
results further demonstrate the utility of HRM for the
detection of somatic mutations in clinical samples and for
screening of samples prior to sequencing.
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